Vertical: CNMBase Year: 2025
Market Size (2025)
$35.63M
Projected (2032)
$47.77M
CAGR (2022–2032)
4.3%
Key Players
8+
Market Overview
The Global Methionine Hydroxy Analog Calcium Salt Market was valued at USD 35.64 Million in 2025 and is projected to reach USD 47.77 Million by 2032, registering a CAGR of 4.27% over 2026–2032. The market expanded from USD 31.42 Million in 2022 to USD 34.17 Million in 2024, and is expected to add USD 12.13 Million in absolute value between 2025 and 2032.
Methionine hydroxy analog calcium salt (MHA-Ca) is the dry calcium salt of 2-hydroxy-4-(methylthio)butanoic acid (HMTBa), a precursor that animals convert to L-methionine. It is used as a supplementary methionine source in compound feed and premixes, principally for poultry, where methionine is typically the first-limiting amino acid in maize–soybean meal diets, and secondarily for swine and other species. Demand is shaped by growth in animal protein production, the adoption of reduced crude-protein diets that depend on supplementary amino acids, and the relative price of competing methionine sources, chiefly DL-methionine and liquid HMTBa.
Key Findings
By Livestock: Poultry is the largest segment, accounting for 70.0% of the market in 2025 (USD 24.94 Million), and is also the fastest-growing segment with a CAGR of 4.50% over 2026–2032.
By Physical Form: Powder is the largest segment with a 90.0% share in 2025 (USD 32.07 Million), while Others is the fastest-growing segment with a CAGR of 5.48%.
By Region: Asia Pacific is the leading region with 42.0% of 2025 value (USD 14.97 Million). Middle East & Africa is the fastest-growing region with a CAGR of 5.92%. North America and Europe each held 18.0% of the market in 2025.
By Country: China is the leading country, valued at USD 6.74 Million in 2025 (18.9% of the global market), followed by U.S. at USD 4.49 Million. Saudi Arabia is the fastest-growing country with a CAGR of 7.43% over 2026–2032.
Segmentation Summary
The market is analysed by livestock (Poultry; Swine & Others) and by physical form (Powder; Others), across five regions and their constituent countries. Poultry generated USD 24.94 Million in 2025 and is forecast to reach USD 33.94 Million by 2032, while Swine & Others is forecast to grow from USD 10.69 Million to USD 13.83 Million at a CAGR of 3.74%. By physical form, Powder is expected to rise from USD 32.07 Million to USD 42.59 Million (CAGR 4.13%), and Others from USD 3.56 Million to USD 5.18 Million.
Regionally, Asia Pacific is projected to grow from USD 14.97 Million in 2025 to USD 21.13 Million in 2032 at a CAGR of 5.05%, contributing USD 6.17 Million of the USD 12.13 Million absolute increase in global value. Latin America (CAGR 4.79%) and Middle East & Africa (CAGR 5.92%) are also expected to outpace the global average, whereas North America (CAGR 2.94%) and Europe (CAGR 2.56%) represent mature markets with slower growth.
Competitive Landscape Summary
Supply of methionine hydroxy analogue products is concentrated among a small number of integrated chemical producers that control the acrolein, methyl mercaptan and hydrogen cyanide chemistry required to make HMTBa. Novus International is the principal supplier of a branded dry HMTBa calcium-salt product (MHA® Feed Additive) alongside its liquid ALIMET®. Adisseo is the largest producer of liquid HMTBa (Rhodimet® AT88), and Chinese producers Zhejiang NHU (through a joint venture with Sinopec Zhenhai Refining) and Sichuan Hebang are expanding HMTBa capacity. The market is also shaped by suppliers of competing DL-methionine and L-methionine, including Evonik, Sumitomo Chemical, Unisplendour Tianhua and CJ CheilJedang, whose pricing sets the reference cost per unit of methionine activity against which MHA-Ca is evaluated.
Challenges and Opportunities
The principal challenges are cyclical methionine pricing driven by large capacity additions, continuing debate among nutritionists over the relative bioefficacy of HMTBa compared with DL-methionine, exposure to petrochemical feedstock costs, and animal-disease shocks such as African swine fever and highly pathogenic avian influenza that disrupt feed demand. Opportunities arise from the expansion of commercial poultry production in South and Southeast Asia, the Middle East and Africa; from low crude-protein feeding programmes that increase reliance on supplementary amino acids; and from the functional attributes of MHA-Ca, including its organic acid character, nitrogen-free composition and dry, premix-compatible form, which suit feed mills that do not operate liquid dosing systems.
Future Outlook
Over 2026–2032 the market is expected to grow steadily at 4.27% per year, with growth increasingly weighted towards emerging poultry-producing economies. Asia Pacific is projected to account for 44.2% of global value in 2032, compared with 42.0% in 2025. Product differentiation is likely to centre on handling characteristics (dust-reduced and granular presentations), consistency of methionine activity, and technical support for formulation, while supply-side competition will continue to be influenced by large-scale methionine capacity additions in China.
The Methionine Hydroxy Analog Calcium Salt Market market is projected to grow at a CAGR of 4.3% from 2022 to 2032.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansDefinition
Methionine hydroxy analog calcium salt (MHA-Ca), also referred to as the calcium salt of DL-2-hydroxy-4-(methylthio)butanoic acid or HMTBa-Ca, is a feed-grade nutritional additive used as a source of methionine activity in animal diets. Chemically, it is formed by neutralising HMTBa with a calcium source such as calcium hydroxide or calcium oxide, yielding a dry product that contains roughly 12% calcium. HMTBa carries a hydroxyl group in place of the amino group of methionine; after absorption, it is oxidised and transaminated in animal tissues to L-methionine, which is then used for protein synthesis and as a methyl donor.
Commercial MHA-Ca is supplied as a free-flowing powder or as granular and other dry presentations, commonly with a declared methionine activity in the region of 84%. It is recognised in the United States as generally recognised as safe (GRAS) for use in animal feed under 21 CFR 582.5477 and is authorised in the European Union as a nutritional additive for all animal species under Commission Implementing Regulation (EU) 2019/8.
Included in the scope:
Feed-grade methionine hydroxy analog calcium salt in powder form and in other dry forms (granular, micro-granulated and similar presentations).
MHA-Ca used in compound feed, premixes, concentrates and supplements for poultry, swine and other livestock species.
Sales by manufacturers and distributors, valued at manufacturer/first-sale level in USD Million.
Excluded from the scope:
Liquid HMTBa (free-acid form, typically about 88% active), DL-methionine, L-methionine and rumen-protected methionine products, except where discussed as competing methionine sources.
HMTBa-based trace mineral chelates (e.g., zinc, copper and manganese HMTBa chelates), where HMTBa is used as a ligand rather than as a methionine source.
Pharmaceutical, nutraceutical and human dietary uses of methionine analogues.
Scope of the Study
This study quantifies the Global Methionine Hydroxy Analog Calcium Salt Market by value for the historic period 2022–2024, the base year 2025 and the forecast period 2026–2032. All values are presented in USD Million, and growth rates are expressed as the compound annual growth rate (CAGR) for 2026–2032.
Research Objectives
To estimate the size of the Global Methionine Hydroxy Analog Calcium Salt Market for 2022–2025 and to forecast its value through 2032 in USD Million.
To analyse market demand by livestock category (Poultry; Swine & Others) and by physical form (Powder; Others), identifying the largest and fastest-growing segments.
To assess regional and country-level demand across North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
To evaluate the drivers, restraints, opportunities and challenges affecting the use of MHA-Ca relative to DL-methionine and liquid HMTBa.
To examine the value chain from petrochemical precursors (acrolein, methyl mercaptan, hydrogen cyanide) through HMTBa synthesis, calcium-salt conversion and distribution to feed mills and integrators.
To review the regulatory frameworks governing methionine hydroxy analogues as feed additives in major producing and consuming regions.
To profile the competitive environment, including the positioning of HMTBa and methionine producers and their key developments since 2022.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansOverview of the Research Process
The study follows a structured research process combining secondary research, primary research and analytical modelling. The process began with defining the market and its segmentation, followed by the collection of data on methionine and HMTBa production, feed output and livestock populations. Market values were then estimated through top-down and bottom-up approaches, validated through interactions with industry participants, and triangulated to arrive at final estimates. Forecasts were developed by modelling demand drivers and constraints for each segment, region and country.
Stage 1 – Market definition and scoping: defining the product, its forms and applications, and the segmentation framework.
Stage 2 – Secondary research: compiling data on feed production, livestock output, methionine capacity, trade flows and regulation.
Stage 3 – Primary research: validating assumptions and estimates with supply-side and demand-side participants.
Stage 4 – Market sizing and triangulation: reconciling top-down and bottom-up estimates.
Stage 5 – Forecasting and review: projecting the market to 2032 and conducting internal quality review.
Secondary Research
Secondary research established the baseline for market sizing and provided context on industry structure, pricing and regulation. Sources relevant to the MHA-Ca and feed amino acid industry included:
Industry associations: feed manufacturers’ associations such as the International Feed Industry Federation (IFIF), the European Feed Manufacturers’ Federation (FEFAC), the American Feed Industry Association (AFIA), the China Feed Industry Association and national poultry and pig producer associations.
Government and regulatory bodies: the US Food and Drug Administration (Center for Veterinary Medicine) and USDA, the European Commission and European Food Safety Authority (EFSA), China’s Ministry of Agriculture and Rural Affairs (MARA) and State Administration for Market Regulation (SAMR), Brazil’s Ministry of Agriculture and Livestock (MAPA), and the Canadian Food Inspection Agency (CFIA).
Company filings: annual reports, interim results, stock-exchange announcements and investor presentations of methionine and HMTBa producers, including filings on the Shanghai and Shenzhen stock exchanges.
Trade journals and technical literature: animal nutrition and feed-industry publications, and peer-reviewed studies on the bioavailability of HMTBa and its calcium salt in poultry and swine.
Paid databases: trade statistics, chemical price-assessment services and company information databases used to track methionine prices, capacity and trade.
Primary Research
Primary research was conducted to validate secondary findings, obtain qualitative insight into purchasing behaviour and refine market estimates. Interviews were carried out through telephone, video-conference and email exchanges using structured discussion guides.
Supply-side respondents: product and business managers at HMTBa and methionine producers, technical service nutritionists, regional distributors and premix manufacturers.
Demand-side respondents: feed mill operators, poultry and swine integrators, procurement managers, and independent animal nutrition consultants.
Objectives: to verify product pricing and volume trends, understand the choice between dry MHA-Ca, liquid HMTBa and DL-methionine, assess regional adoption patterns, and validate growth expectations for each segment.
Market Size Estimation
Top-down approach: the overall feed methionine market was estimated from compound feed production and typical methionine inclusion requirements by species. The share of methionine activity supplied in the form of methionine hydroxy analogues, and within it the share supplied as the dry calcium salt, was then applied, using information from company disclosures, trade data and primary interviews.
Bottom-up approach: demand was built up by country from livestock production (broiler, layer and pig output), feed conversion and diet formulation practices, the penetration of MHA-Ca among feed mills and premixers, and average selling prices. Country estimates were aggregated to regional and global totals.
Data triangulation: the results of both approaches were compared and reconciled with supply-side information on production capacity and sales. Where estimates diverged, assumptions were reviewed with industry participants until a consistent set of figures was obtained for each segment, region and country.
Forecasting Methodology
Forecasts for 2026–2032 were developed using a combination of trend analysis and driver-based modelling. Historic growth patterns for 2022–2025 were assessed and adjusted for expected changes in the underlying demand drivers. Factors considered include:
Projected growth in poultry meat, egg and pork production by country.
Compound feed production trends and the adoption of reduced crude-protein diets.
Methionine price outlook, competing source economics and new capacity additions.
Regulatory developments affecting feed additives and antibiotic use in feed.
Macroeconomic conditions, including GDP growth, income levels and protein consumption.
Animal disease risks and their expected impact on livestock populations.
Each segment, region and country was modelled individually, and the results were checked for internal consistency so that segment and country values reconcile with regional and global totals.
Base Year, Forecast Period and Currency
Currency: USD Million, at constant exchange rates; values for non-USD markets were converted using average annual exchange rates for the base year.
Assumptions and Limitations
Methionine prices are assumed to remain cyclical but without extreme, sustained deviations from historic ranges over the forecast period.
No major regulatory restriction on the use of methionine hydroxy analogues in feed is assumed in any key market.
Animal disease outbreaks are assumed to occur at frequencies broadly in line with recent experience, without a pandemic-scale event affecting global livestock output.
Company-level sales of MHA-Ca are rarely disclosed separately from wider methionine or animal nutrition revenues; estimates therefore rely on triangulation and industry interviews.
Market values reflect sales at manufacturer level and exclude downstream value added in premixes and compound feed.
Base Year
2025
Historical Period
2022 – 2024
Forecast Period
2026 – 2032
Primary Interviews
150+
Historical data (2022–2025) and forecast period (2025–2032)
Our research process spans primary interviews with industry stakeholders combined with comprehensive secondary data analysis, validated through triangulation across multiple independent sources.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansIntroduction
The supply side of the methionine hydroxy analogue market is consolidated. The production of HMTBa, the precursor of MHA-Ca, requires integrated access to acrolein, methyl mercaptan and hydrogen cyanide, and only a handful of companies worldwide operate such facilities at scale. Novus International is the principal supplier of a branded dry HMTBa calcium-salt product, while Adisseo, Zhejiang NHU (through its joint venture with Sinopec Zhenhai Refining) and Sichuan Hebang produce liquid HMTBa that can serve as feedstock for calcium-salt conversion. In addition, a number of smaller Chinese producers and traders supply feed-grade MHA-Ca to the domestic and export markets under China’s national standard GB/T 21034-2007.
Competition is shaped by the broader methionine industry. Feed formulators select among dry MHA-Ca, liquid HMTBa, DL-methionine and L-methionine based on cost per unit of methionine activity, handling infrastructure and assumed bioefficacy. As a result, large DL-methionine producers such as Evonik, Sumitomo Chemical and Unisplendour Tianhua, together with L-methionine producer CJ CheilJedang, exert significant influence on MHA-Ca pricing and volumes. Rivalry is intense and is conducted on price, technical service, product format and supply security, with Chinese capacity additions acting as a key source of competitive pressure.
Key Player Positioning
Market Leaders
Novus International, Inc. (St. Charles, Missouri, USA) is owned by Mitsui & Co. and Nippon Soda and traces its methionine hydroxy analogue business to Monsanto. It markets ALIMET® (liquid HMTBa) and MHA® Feed Additive, a dry, granular, non-dusty HMTBa product with 84% methionine activity that supplies organic calcium, as well as MINTREX® HMTBa-chelated trace minerals. As a privately held company, Novus does not publicly disclose its revenue. In June 2025 Novus reorganised into a Methionine Business Unit and a Specialty Business Unit, and it uses exclusive distribution partners in smaller markets.
Adisseo (Bluestar Adisseo Co., Ltd.), part of China National BlueStar within the Sinochem group and listed in Shanghai, describes itself as the global leader in liquid methionine. Its portfolio includes Rhodimet® AT88 (liquid HMTBa) and Rhodimet® NP99 (powder DL-methionine), with production in Nanjing (China), Burgos (Spain) and France. The company reported operating revenue of RMB 17.23 billion for FY2025. It started a 180,000 t/yr liquid methionine plant in Nanjing in 2022 and is building a 150,000 t/yr powder methionine plant in Quanzhou, Fujian.
Evonik Industries AG (Essen, Germany) is one of the world’s largest producers of DL-methionine (MetAMINO®), with production hubs in Antwerp/Wesseling, Mobile (Alabama) and Singapore. Evonik reported group sales of EUR 14.1 billion for FY2025. Although it does not produce HMTBa, its pricing and capacity decisions set a key benchmark for all methionine sources, including MHA-Ca.
Challengers
Zhejiang NHU Co., Ltd. (Shenzhen-listed) produces solid DL-methionine through Shandong NHU Amino Acid Co., Ltd. and entered the liquid methionine segment through a 50:50 joint venture with Sinopec Zhenhai Refining & Chemical for 180,000 t/yr of capacity, which entered trial production in 2025. NHU reported operating revenue of RMB 22.25 billion for FY2025 across its vitamins, amino acids, flavours and new materials businesses.
Sichuan Hebang Biotechnology Co., Ltd. (Shanghai-listed) is a diversified chemical company that operates liquid methionine capacity in Leshan, Sichuan, and in April 2026 announced a 600,000 t/yr green feed-grade liquid methionine project. The company reported revenue of RMB 7.19 billion for FY2025.
Sumitomo Chemical Co., Ltd. (Tokyo, Japan) produces feed-grade DL-methionine at its Ehime Works. Since April 2025, ITOCHU Corporation has acted as the seller of all methionine produced by Sumitomo Chemical, covering more than 70 countries. Sumitomo Chemical reported sales revenue of JPY 2,328.5 billion for the fiscal year ended March 2026.
Niche and Regional Players
Chongqing Unisplendour Tianhua Methionine Co. is a Chinese DL-methionine producer with operations in Chongqing and Ningxia and was among the first domestic producers to reduce China’s dependence on imported methionine. Its revenue is not publicly disclosed separately.
CJ CheilJedang Corporation (Seoul, South Korea) produces L-methionine in Kerteh, Malaysia, as part of its Bio division, which reported revenue of KRW 3.96 trillion for FY2025. Its L-methionine competes with other methionine sources in poultry and swine feed in Asia and other export markets.
In addition, a number of smaller Chinese manufacturers and trading companies supply feed-grade MHA-Ca powder, primarily to domestic feed mills and premixers and to export markets in Asia, the Middle East and Africa.
Competitor Dashboard
The dashboard below provides a qualitative assessment of the profiled companies across four parameters relevant to competitiveness in the market.
Threat of New Entrants – Low
HMTBa production requires large-scale, capital-intensive plants and the safe handling of hydrogen cyanide, acrolein and methyl mercaptan.
Process technology is protected by patents and know-how held by a small number of producers.
Regulatory authorisation, product registration and established customer relationships raise the cost of market entry.
Bargaining Power of Suppliers – Medium
Key intermediates are commodity petrochemicals, but their supply is often tied to specific integrated complexes.
Large producers are backward-integrated, which limits supplier leverage over them, whereas non-integrated calcium-salt converters depend on purchased HMTBa.
Energy and feedstock price swings are passed through the chain and affect production costs.
Bargaining Power of Buyers – High
Large integrators and feed manufacturers purchase in volume and use least-cost formulation software to compare methionine sources.
Switching between MHA-Ca, liquid HMTBa and DL-methionine is technically straightforward for mills with suitable equipment.
Buyers are price-sensitive because feed accounts for the majority of livestock production costs.
Threat of Substitutes – High
DL-methionine, liquid HMTBa and L-methionine provide the same nutritional function and are widely available.
Substitution decisions are driven by cost per unit of methionine activity and assumed bioefficacy.
Large DL-methionine capacity additions can quickly alter the relative economics of methionine sources.
Intensity of Competitive Rivalry – High
A small number of global producers compete intensively across methionine forms and regions.
Chinese producers are expanding capacity and competing on cost.
Competition extends beyond price to technical service, product format and supply reliability.
Threat of New Entrants: Low; High capital requirements, hazardous chemistry, proprietary know-how.
Bargaining Power of Suppliers: Medium; Commodity inputs but integrated supply; feedstock price pass-through.
Bargaining Power of Buyers: High; Concentrated, price-sensitive buyers using least-cost formulation.
Threat of Substitutes: High; DL-methionine, liquid HMTBa and L-methionine readily available.
Competitive Rivalry: High; Few large producers, Chinese capacity growth, cyclical prices.
Market estimates by geography (2032)
InsightAsia Pacific leads with $21.13M by 2032, while Middle East & Africa is projected to grow fastest at a 5.9% CAGR.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription Plans| REGION | 2022 | 2025 | 2032 | CAGR | SHARE |
|---|---|---|---|---|---|
| North America | $5.83M | $6.80M | $7.86M | 3.0% | 16% |
| Europe | $5.88M | $6.76M | $7.66M | 2.7% | 16% |
| Asia Pacific | $12.94M | $16.52M | $21.13M | 5.0% | 44% |
| Latin America | $4.96M | $6.26M | $7.91M | 4.8% | 17% |
| Middle East & Africa | $1.81M | $2.40M | $3.20M | 5.9% | 7% |
| Total | $31.42M | $38.75M | $47.77M | 4.3% | 100% |
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansTotal Market Size
$47.77M
| APPLICATION | REVENUE ($B) | GROWTH RATE | MARKET PENETRATION |
|---|---|---|---|
| Poultry | $33.94M | 4.5% | 71% |
| Swine & Others | $13.83M | 3.8% | 29% |
* Revenue projections based on 2025 estimates. Growth rates represent CAGR 2024–2030. Market penetration indicates current adoption rate within addressable market segments.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSee plans for professionals or small and medium businesses.
Analytical insights on Methionine Hydroxy Analog Calcium Salt Market covering market dynamics, competitive landscape, and strategic outlook.
The Methionine Hydroxy Analog Calcium Salt Market market is projected to reach $47.77M by 2032, growing at 4.3% CAGR. The Poultry segment holds the largest share.
Demand for MHA-Ca is a function of the volume of compound feed produced for monogastric animals, the methionine requirement built into feed formulations, and the competitiveness of MHA-Ca against other methionine sources. This chapter examines the factors expected to influence the market between 2026 and 2032. The growth factor analysis in Section 4.2 rates five macro-level and five micro-level factors by impact type and assigns impact scores out of 10 for three sub-periods; these scores are analyst assessments based on the secondary and primary research described in Chapter 3, where a higher score indicates a stronger influence on the market.
Growing Global Poultry Production and Animal Protein Demand
Poultry is the most widely consumed meat globally and continues to gain share in total meat consumption owing to its lower cost, short production cycle, efficient feed conversion and absence of religious restrictions. Population growth, urbanisation and rising incomes in Asia, Latin America, the Middle East and Africa are expanding demand for chicken meat and eggs, and production is increasingly organised through vertically integrated companies operating commercial feed mills. Because methionine is usually the first-limiting amino acid in maize–soybean meal broiler and layer diets, nearly all commercial poultry feed includes a supplementary methionine source. Every increase in commercial broiler and layer output therefore raises the base demand for methionine activity, including the share supplied as MHA-Ca. This structural link explains why Poultry accounted for 70.0% of the market in 2025 and is expected to grow at 4.50% per year through 2032. National programmes to raise domestic poultry self-sufficiency, such as those in Saudi Arabia and other Gulf states, add further investment in integrated poultry operations and feed capacity.
Adoption of Reduced Crude-Protein Diets
Feed formulators are progressively lowering dietary crude protein while balancing essential amino acids with supplementary sources. This approach reduces reliance on soybean meal, lowers nitrogen excretion and ammonia emissions, and can improve gut health. Environmental policy has reinforced the trend: nitrogen and ammonia emission controls in the European Union encourage precision amino acid nutrition, and in April 2023 China’s Ministry of Agriculture and Rural Affairs issued a three-year action plan to reduce and substitute soybean meal in feed, promoting low-protein diets supplemented with synthetic amino acids. As crude protein is reduced, the inclusion rate of supplementary methionine rises, increasing demand for all methionine sources, including MHA-Ca. Low-protein formulation also increases the value of accurate dosing and consistent methionine activity, which favours established suppliers with technical service capability.
Restrictions on Antibiotic Growth Promoters and Focus on Gut Health
The European Union banned antibiotics as growth promoters in feed from 2006, and China prohibited growth-promoting antibiotics in commercial feed from 2020 under MARA Announcement No. 194. Similar restrictions and voluntary antibiotic-free programmes have spread across other markets. These changes have increased interest in nutritional strategies that support gut integrity and performance without antibiotics. HMTBa is an organic acid, and suppliers position HMTBa-based products as contributing antimicrobial and antioxidant benefits in addition to methionine activity. MHA-Ca additionally supplies calcium in an organic form and is nitrogen-free. These attributes allow suppliers to differentiate MHA-Ca on functional value rather than on price per unit of methionine alone, supporting its use in premium and antibiotic-free production systems.
Expansion of Commercial Feed Milling in Emerging Markets
The shift from backyard to commercial livestock production in South and Southeast Asia, Africa and parts of Latin America is increasing the volume of industrially produced compound feed. Many of the new and mid-sized feed mills and premix plants in these markets are designed around dry ingredient handling and lack the storage tanks, heated lines and spray systems required to dose liquid HMTBa. For these operations, a dry calcium-salt form of HMTBa can be weighed and blended with existing equipment, providing a convenient alternative to liquid products. This dynamic underpins faster growth in India (CAGR 6.82%), Saudi Arabia (CAGR 7.43%) and the UAE (CAGR 6.57%) than in mature markets.
Growth in South Asia, Southeast Asia, the Middle East and Africa
India, Southeast Asian economies, the Gulf states and sub-Saharan Africa are among the fastest-growing poultry markets. In this report, India is projected to grow at 6.82% and Middle East & Africa at 5.92% over 2026–2032. Suppliers that establish distribution partnerships with local premixers and integrators, and that provide formulation support, are positioned to capture this incremental demand.
Dust-Reduced and Granular Product Formats
Feed mills are paying closer attention to occupational dust exposure, flowability and segregation in premixes. Granular and other non-powder forms of MHA-Ca address these concerns and are reflected in the faster growth of the Others physical form segment (CAGR 5.48%) compared with Powder (CAGR 4.13%). Product development in coated, granulated and blended formats offers suppliers a route to differentiation and improved pricing.
Applications Beyond Poultry
Research on the bioavailability of HMTBa calcium salt in nursery pigs, together with interest in methionine nutrition for aquaculture and ruminants, provides scope to broaden usage beyond poultry. The Swine & Others segment is projected to grow from USD 10.69 Million in 2025 to USD 13.83 Million in 2032, and targeted technical programmes for swine and other species could support stronger penetration.
Competition from DL-Methionine and Cyclical Methionine Pricing
DL-methionine is the dominant form of supplementary methionine worldwide and is produced at very large scale by Evonik, Adisseo, Sumitomo Chemical and several Chinese producers. Substantial capacity additions, particularly in China, have historically produced periods of oversupply and steep price declines, which compress margins across all methionine sources. Because feed formulators compare sources on cost per unit of methionine activity, low DL-methionine prices can lead mills to shift volumes away from MHA-Ca. Price increases announced by major producers in 2026 illustrate the cyclical nature of the market, and such cycles make demand for any single methionine form sensitive to relative pricing.
Debate over Relative Bioefficacy
The relative bioefficacy of HMTBa products compared with DL-methionine has been debated in animal nutrition research for several decades, with published estimates varying by study design, species and response criteria. In its assessment of a product combining HMTBa and its calcium salt, EFSA concluded that the additive is an effective source of methionine for non-ruminant species but noted that HMTBa may be less bioefficacious than DL-methionine. Uncertainty over the appropriate replacement ratio can lead conservative formulators to favour DL-methionine or to apply cautious matrix values to MHA-Ca, which limits its competitiveness in price-sensitive markets.
Feedstock and Production Cost Exposure
HMTBa production depends on petrochemical intermediates, including propylene-derived acrolein, methanol-derived methyl mercaptan, hydrogen cyanide and sulfuric acid, together with lime for calcium-salt conversion. These inputs are hazardous and require integrated, capital-intensive facilities. Fluctuations in energy and petrochemical prices, and the cost of complying with process-safety and environmental regulations, can raise production costs and limit the ability of MHA-Ca suppliers to compete on price.
Capacity Build-Out of HMTBa in China
Since 2022, Chinese producers have added significant liquid methionine (HMTBa) capacity, including Adisseo’s 180,000 t/yr plant in Nanjing, the 180,000 t/yr joint venture between Zhejiang NHU and Sinopec Zhenhai Refining, which entered trial production in 2025, and Sichuan Hebang’s announced 600,000 t/yr project. Greater availability of HMTBa as a raw material for calcium-salt conversion is likely to increase regional supply of MHA-Ca and intensify price competition.
Sustainability and Carbon Footprint Considerations
Integrators and feed companies are increasingly measuring the environmental footprint of feed ingredients. Amino acid supplementation that allows lower dietary protein can reduce nitrogen excretion and land use associated with soybean meal, while producers are under pressure to document the carbon footprint of their own manufacturing processes. Suppliers able to provide verified environmental data are likely to gain preference in contracts with large integrators and retailers.
Animal Disease Outbreaks
African swine fever has caused major reductions in pig herds in China and Southeast Asia and continues to affect parts of Europe, while highly pathogenic avian influenza has led to large-scale culling of poultry in North America, Europe and Asia. These outbreaks create abrupt swings in feed demand and complicate demand planning for additive suppliers.
Consolidation and Realignment Among Suppliers
Leading suppliers are reorganising their methionine businesses to improve cost competitiveness. Evonik restructured its Animal Nutrition business in 2023, Novus International separated its methionine and specialty operations into two business units in 2025, and Sumitomo Chemical transferred global sales of its methionine to ITOCHU from April 2025. Such realignment points to an increasingly cost-focused competitive environment.
The value chain of the MHA-Ca market extends from petrochemical raw materials to livestock producers. Value is concentrated at the manufacturing stage, where control of the hazardous precursor chemistry and process know-how creates high barriers to entry.
Raw Materials and Inputs
The principal inputs are acrolein (produced by the oxidation of propylene), methyl mercaptan (produced from methanol and hydrogen sulfide), hydrogen cyanide, sulfuric acid and a calcium source such as calcium hydroxide or calcium oxide. Most large HMTBa producers are backward-integrated into one or more of these intermediates, often within petrochemical complexes, to secure supply and manage the handling of toxic materials.
Manufacturing
Acrolein and methyl mercaptan are reacted to form 3-(methylthio)propionaldehyde (MMP), which is converted with hydrogen cyanide into the corresponding cyanohydrin. Hydrolysis of the cyanohydrin with sulfuric acid yields HMTBa. To produce MHA-Ca, HMTBa is neutralised with calcium hydroxide or calcium oxide, and the resulting salt is dried, milled or granulated, and packed. Quality parameters include methionine activity, calcium content, moisture, heavy metals and particle size.
Distribution and Channels
MHA-Ca reaches the market through direct sales to large integrators and compound feed manufacturers, through premix producers who incorporate it into vitamin–mineral–amino acid premixes, and through regional distributors and trading houses serving smaller mills. Technical service, including formulation support and laboratory analysis, is an important part of the commercial offering.
End Users
End users are poultry integrators (broilers, layers, breeders and turkeys), pig producers and other livestock operations, either directly through their in-house feed mills or indirectly through commercial feed purchases.
North America
United States: Methionine hydroxy analog and its calcium salts are listed under 21 CFR 582.5477 as generally recognised as safe when used in animal feed in accordance with good manufacturing or feeding practice. Feed manufacturing is subject to the Current Good Manufacturing Practice and Preventive Controls for Animal Food rule (21 CFR Part 507) under the Food Safety Modernization Act, overseen by the FDA Center for Veterinary Medicine. Ingredient definitions published by the Association of American Feed Control Officials (AAFCO) are widely referenced in state feed laws.
Canada: Livestock feeds, including feed ingredients, are regulated by the Canadian Food Inspection Agency under the Feeds Act and Feeds Regulations.
Mexico: Feed ingredients and additives are regulated by the National Service of Agro-Alimentary Health, Safety and Quality (SENASICA) under the Ministry of Agriculture and Rural Development.
Europe
Regulation (EC) No 1831/2003 governs the authorisation, supervision and labelling of feed additives; additives must be authorised and entered in the EU Register of Feed Additives.
Commission Implementing Regulation (EU) 2019/8 authorises hydroxy analogue of methionine and its calcium salt as a nutritional feed additive for all animal species, following a scientific assessment by EFSA.
Regulation (EC) No 183/2005 sets requirements for feed hygiene, and Regulation (EC) No 767/2009 governs the placing on the market and labelling of feed.
United Kingdom: Following its exit from the EU, the UK maintains a retained feed additive authorisation regime administered by the Food Standards Agency.
Asia Pacific
China: Feed additives are governed by the Regulations on the Administration of Feed and Feed Additives and must appear in the Feed Additive Catalogue issued by MARA (Announcement No. 2045). National standard GB/T 21034-2007 specifies requirements for the feed additive methionine hydroxy analogue calcium. MARA Announcement No. 194 prohibited growth-promoting antibiotics in commercial feed from 2020.
Japan: Feed and feed additives are regulated under the Act on Safety Assurance and Quality Improvement of Feed, with inspection and analysis supported by the Food and Agricultural Materials Inspection Center (FAMIC).
India: The Bureau of Indian Standards publishes specifications for compounded feeds, including poultry feeds (IS 1374), and feed-industry quality is supported by the Department of Animal Husbandry and Dairying.
Latin America
Brazil: The Ministry of Agriculture and Livestock (MAPA) regulates feed products under Law No. 6,198/1974 and Decree No. 6,296/2007, which require registration of establishments and products, including feed additives.
Argentina: The National Agri-Food Health and Quality Service (SENASA) regulates the registration of feed products and additives.
Middle East & Africa
Saudi Arabia: The Saudi Food and Drug Authority (SFDA) regulates the registration and import of animal feed and feed additives.
South Africa: Farm feeds are regulated under the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947 (Act No. 36 of 1947), administered by the Department of Agriculture.
United Arab Emirates: The Ministry of Climate Change and Environment oversees the registration of animal feed products.
Sep 2022: Adisseo; Expansion; Started its 180,000 t/yr liquid methionine plant (BANC2) in Nanjing, raising site capacity to 350,000 t/yr.
Jan 2023: Zhejiang NHU; Joint Venture; Signed a 50:50 joint venture agreement with Sinopec Zhenhai Refining & Chemical for 180,000 t/yr of liquid methionine capacity.
Jan 2023: Novus International; Acquisition; Acquired biotechnology company Agrivida and its INTERIUS grain-embedded feed additive technology.
Jan 2023: Adisseo; Acquisition; Acquired Nor-Feed, a French producer of plant-extract feed additives.
Apr 2023: Evonik; Restructuring; Reorganised Animal Nutrition into separate amino acid and specialty businesses to improve competitiveness.
Jun 2023: Novus International; Rebranding; Launched a global rebrand around “intelligent nutrition” covering ALIMET®, MHA® and MINTREX®.
Aug 2023: Adisseo; Expansion; Announced a 150,000 t/yr powder methionine plant in Quanzhou, Fujian, with start-up targeted for 2027.
Feb 2024: Novus International; Partnership; Appointed Halchemix as exclusive distributor of MHA® and MINTREX® in Canada, effective March 2024.
Aug 2024: Evonik; Expansion; Inaugurated a 40,000 t/yr methionine expansion in Singapore, raising site capacity to 340,000 t/yr.
Feb 2025: Sumitomo Chemical; Partnership; Agreed that ITOCHU would sell all methionine produced by Sumitomo Chemical from April 2025.
Mar 2025: Evonik; Investment; Invested in upgrading its Antwerp/Wesseling methionine production network.
Jun 2025: Novus International; Restructuring; Realigned into a Methionine Business Unit and a Specialty Business Unit.
Jun 2025: Zhejiang NHU; Expansion; Liquid methionine joint venture with Sinopec Zhenhai entered trial production and produced qualified product.
Dec 2025: Adisseo; Financing; Completed a private placement of A-shares raising approximately RMB 3.0 billion.
Mar 2026: Evonik; Pricing; Announced a 10% global price increase for MetAMINO® DL-methionine.
Apr 2026: Sichuan Hebang; Expansion; Announced a 600,000 t/yr green feed-grade liquid methionine project in Leshan, Sichuan.
Political
Government food-security programmes in the Gulf states, India and Africa support investment in domestic poultry and feed production.
Trade tensions and tariffs can affect cross-border flows of methionine and HMTBa between China, the United States and Europe.
State-supported capacity expansion in China influences global supply and pricing.
Economic
Methionine prices are cyclical and sensitive to capacity additions, affecting the relative economics of MHA-Ca.
Feed grain and soybean meal prices influence formulation decisions and amino acid inclusion rates.
Income growth in emerging economies raises per-capita animal protein consumption.
Social
Rising consumer preference for affordable protein supports poultry production growth.
Consumer and retailer demand for antibiotic-free meat encourages nutritional approaches to gut health.
Growing attention to animal welfare influences production systems and feed specifications.
Technological
Process improvements in HMTBa synthesis and calcium-salt granulation improve cost and product quality.
Least-cost formulation software and precision nutrition enable accurate amino acid supplementation.
Research on bioavailability and functional effects of HMTBa informs matrix values used by nutritionists.
Environmental
Nitrogen and ammonia emission policies encourage low crude-protein diets supplemented with amino acids.
Reduced soybean meal use lowers the land-use footprint associated with feed.
Producers face scrutiny of emissions and hazardous chemical handling at manufacturing sites.
Legal
Feed additives require authorisation (e.g., EU Regulation (EC) No 1831/2003; China Feed Additive Catalogue).
Product standards such as China’s GB/T 21034-2007 set quality requirements for MHA-Ca.
Process-safety and environmental permitting regulations govern the handling of hydrogen cyanide and acrolein.
Profiles of 28 companies operating in the Methionine Hydroxy Analog Calcium Salt Market market, including revenue, employee count, and market positioning where available.
Showing 28 of 28 companies
Evonik is Germany's second-largest listed chemicals group after BASF and one of Europe's broadest pure-play specialty chemicals companies, generating €14.1bn of sales and €1.87bn adjusted EBITDA in FY2025. Since April 2025 it has been organised into two operating segments — Custom Solutions (formulated, application-driven specialties for coatings, personal care, pharma, and industrial additives) and Advanced Technologies (scale- and technology-driven platforms in silica, hydrogen peroxide, high-performance polymers, crosslinkers and animal-nutrition amino acids) — plus an Infrastructure segment (SYNEQT site services, Oxeno C4 chemicals) earmarked for divestment. Its competitive identity rests on deep process know-how, integrated German Verbund sites (Marl, Wesseling, Rheinfelden, Essen, Hanau), and leadership positions in global niches (fumed silica, DL-methionine, PA12, pharma excipients/lipids). The investment case is a transformation story — €400m-plus cost reduction, portfolio pruning, deleveraging — now overlaid by a live takeover approach from BASF and a near-majority foundation shareholder whose stance is pivotal. --- ### Company self-description Evonik describes itself as a global chemical company that goes "beyond chemistry" by combining innovative strength with leading technological expertise, providing customers with a competitive advantage through tailor-made products and solutions — positioning itself as a "superforce for industry" (company boilerplate, press releases 2026; Company Factbook 2026). Its stated strategic pillars (Capital Markets Day, 22 May 2025) are: a differentiated portfolio in two segments, sustainable innovation, a balanced regional footprint (ambition of roughly one-third of sales in each of Americas, EMEA and Asia-Pacific), and a performance culture. ### Independent characterisation Evonik is a mid-cap, diversified specialty and "semi-specialty" chemicals manufacturer. Roughly 80% of FY2025 sales (€11.5bn of €14.1bn) came from the two core segments; the remaining ~18–19% came from Infrastructure & Other, which bundles low-margin site services and the cyclical C4 (Oxeno) petrochemical chain. The business is overwhelmingly a product business (manufactured chemicals sold B2B under supply contracts, frame agreements and spot), with smaller service/contract components: (i) pharma CDMO and contract manufacturing (Health Care — lipids/LNPs, drug substances, oral drug delivery), (ii) site infrastructure and utility services sold by SYNEQT to ~two dozen third-party companies in the Marl and Wesseling chemical parks, and (iii) licensing/technology (e.g., HPPO hydrogen peroxide technology with partners; catalysts). Subscription revenue is negligible. Precise revenue-model split (product vs service vs licensing) is n/d. ### Value-chain position Evonik sits mid-stream: it buys petrochemical feedstocks (C4 raffinate, propylene, methanol, ammonia, natural gas/energy, silicon metal, sulphur) and converts them into intermediates and formulated specialties sold to formulators and OEMs. Upstream integration is partial (own C4 cracking downstream of refinery/cracker streams at Marl and Antwerp; own HCN and methionine chain in Antwerp, Mobile and Singapore). Downstream, it rarely sells to consumers; its products are ingredients typically <5% of the customer's cost but critical to performance ("small cost share, high value-in-use"), which supports pricing power in the specialty businesses. ### Customer types and end markets Customers include paint and coatings formulators, adhesives and sealants makers, tyre and rubber producers (silica/silanes), cosmetic and household-care brands, pharmaceutical and biotech companies (excipients, lipids, CDMO), animal-feed mills and integrators (methionine), plastics and automotive suppliers (PA12, PEEK), aerospace (ROHACELL foams), pulp & paper, electronics and semiconductors (high-purity silanes/chlorosilanes, H2O2), renewable energy and hydrogen (membranes, catalysts), and biodiesel producers (alkoxide catalysts). End-market exposure is broad: consumer/personal care, health care, food/feed, automotive and mobility, construction, coatings, industrial, energy/agriculture. A precise end-market % split for FY2025 is n/d in sources reviewed.
Company Headquarters: Missouri, US Founded: 1991 Workforce: ~800+ Company Working: Novus International manufactures animal health and nutrition products for livestock, poultry, and aquaculture. The products offered by the company include various preservative premixtures, feed supplements, feed additives, nutritional feed acids, chelated trace minerals, feed preservatives, feed antioxidants, and other specialty ingredients. Under its eubiotics products category, the company offers ACIDOMIX, a uniquely formulated blend of organic acids which ensures delivery of its acidification to the lower digestive tract. In addition to its preserving effects, the product has antimicrobial effects that help reduce bacterial contamination levels and energy waste resulting in optimal growth rates. The company has research & development laboratories and manufacturing facilities in more than 35 countries, as well as offices with field staff in an additional 60 countries. Novus International operates as a subsidiary of Mitsui & Co. (U.S.A.) Inc. and Nippon Soda Co., Ltd.
DuPont de Nemours today is a focused, roughly USD 7 bn-revenue multi-industry company. It is no longer the diversified chemical conglomerate of its heritage. After a decade of portfolio surgery, the company consists of two segments: **Healthcare & Water Technologies (about 47% of FY2025 sales):** Tyvek® medical packaging and protective garments, specialty medical device components (Spectrum, Donatelle), and the FilmTec™ / Amberlite™ water purification franchise. **Diversified Industrials (about 53%):** Building envelope products (Tyvek® house wrap, Styrofoam™, Corian®) and engineered industrial technologies (Molykote®, Vespel®, Betaseal™/Betaforce™ adhesives, Cyrel® printing plates). The company earns a premium-specialty margin profile: operating EBITDA margin was 23.8% in FY2025, with guidance of about 24.5% for FY2026. Management targets 3–4% organic growth, 150–200 bps of margin expansion and 8–10% adjusted EPS CAGR through 2028, supported by a lightly levered BBB+/Baa1 balance sheet. The principal overhang is legacy PFAS liability, shared with Chemours, Corteva and Qnity under contractual arrangements. The principal opportunity is a cleaner, higher-growth healthcare/water mix and capital redeployment. --- **Company's own description (FY2025 10-K, Item 1).** DuPont describes itself as a leading provider of advanced solutions that improve everyday life across healthcare, water, construction and industrial markets. It emphasizes helping customers advance their technology pipelines, from clean water to medical packaging that enhances safety and performance. It names its competitive strengths as: - proprietary product and process technologies; - robust application-development pipelines; - well-known brands; - customer intimacy; - global manufacturing and local service capability. **Independent characterization.** DuPont is now best understood as a specialty engineered-materials and components company with four businesses of roughly comparable scale: **Business model and revenue model.** - Revenue is overwhelmingly product sales: materials, components, membranes, resins, garments and plates. Some engineered systems and modules are sold in Water. - There is no material subscription or licensing revenue. Trade secrets may be licensed occasionally (10-K, Intellectual Property). - The contract manufacturing and design services of Spectrum and Donatelle (medical devices) add a design-in / build-to-print services element, but are recognized as product revenue. - Seasonality: North American Building Technologies demand peaks in Q2–Q3. **Value-chain position.** DuPont sits mid-stream as a Tier-1/Tier-2 supplier. It converts purchased raw materials (polyolefins, specialty monomers, resins, silicones, polymers) into engineered materials, membranes and components. These are specified into customers' finished products: medical devices, sterile packaging, water plants, building envelopes, aircraft, vehicles and print packaging. **Customer types.** - Medical device OEMs and sterile packaging converters - Biopharma manufacturers - Industrial end users and EPC/OEM water-system integrators - Municipalities and desalination operators (via integrators) - Builders, contractors and distributors (e.g., Corian® distribution through Hallmark and Parksite) - Automotive and EV OEMs and Tier-1s - Aerospace OEMs - Printing and packaging converters Most products are sold through DuPont's own sales organization, with distributors used for some lines (10-K, Distribution). **End markets.** Healthcare (medical devices, packaging, biopharma, PPE), water (industrial, municipal/desalination, life sciences, microelectronics UPW), construction (residential, non-residential, repair/remodel) and industrial (aerospace, automotive/EV, printing and packaging, general industrial).
Nippon Soda is a mid-cap, diversified Japanese chemical group founded in 1920 as a chlor-alkali producer and progressively re-shaped into a portfolio anchored by two high-value franchises: research-based crop protection (Agri Business, 35% of FY3/26 sales) and specialty "Chemical Materials" (25%), complemented by lower-margin but stable trading/logistics, plant engineering and environmental-recycling businesses. Its crown jewels are niche, high-barrier products in which it holds globally relevant positions — the pharmaceutical excipient NISSO HPC (hydroxypropyl cellulose), liquid polybutadiene NISSO-PB for AI-server copper-clad laminates, KrF photoresist polymer VP-POLYMER, and proprietary agrochemicals such as Mospilan (acetamiprid) and Topsin-M. With FY3/26 net sales of JPY 152.1 billion, record net profit of JPY 18.3 billion, an equity ratio of ~66.6%, and a 50%+ total shareholder return policy, the company is a conservatively financed, R&D-led specialty player now pivoting toward healthcare (including animal health) and advanced ICT materials under its Stage III plan to FY3/30. --- ### Company's own description According to its Stage III medium-term plan (May 2026), Nippon Soda describes its mission as creating new value through the power of chemistry, and frames the group as supporting everyday life through chemical products and services across four "material" fields: Agriculture (securing food and sustainable agriculture), Healthcare (healthy life for all people), Environment (toward a resource-recycling society) and ICT (chemical functions for IT devices). The Yuho describes the parent's business as manufacturing, processing and marketing of industrial chemicals, synthetic resins and plastics, dyes, pharmaceuticals, agrochemicals, veterinary pharmaceuticals and other chemical products. ### Business model and revenue model Nippon Soda's revenue is overwhelmingly product-based (manufactured chemical sales), with secondary service revenues from logistics (warehousing, transport, customs brokerage), engineering/EPC contracts and waste treatment. There is no material subscription revenue. Licensing/active-ingredient supply is embedded in Agri Business: the company supplies proprietary active ingredients (AIs) to global majors and sells formulated products through its own overseas network and partners. The revenue mix by nature (approximation from FY3/26 segment data; company does not disclose a product/service split): *Note: the above split is an analytical characterization; the company does not report revenue by nature.* ### Value-chain position **Agri Business:** fully integrated R&D-type agrochemical originator — chemical synthesis, biological/safety research, formulation research, field evaluation, AI manufacturing (including via Nisso Namhae Agro in Korea) and formulation, registration and global marketing (Stage III plan). The company emphasizes that R&D-type agrochemical originators are largely limited to five overseas majors plus Japanese firms, and that Japanese originators punch above their weight in new AI discovery. **Chemical Materials:** upstream chlor-alkali (caustic soda, chlorine, hydrochloric acid) feeding downstream fine/specialty chemistry (living anionic polymerization for NISSO-PB and VP-POLYMER; cellulose derivatization for HPC; penem API synthesis). **Trading & Logistics:** captive and third-party distribution (Nisso Shoji) and specialized hazardous/pharma logistics (Sanwa Soko, Sanso Unyu). **Engineering:** fine-chemical-type EPC (Nisso Engineering) and civil works (Nisso Kensetsu). **Eco Solutions:** waste treatment, zinc recovery from electric-arc-furnace dust, sulfuric acid recycling (Nisso Metallochemical). ### Customer types and end-markets Customers include global agrochemical majors and distributors, farmers' cooperatives (via channels), generic and innovator pharmaceutical companies and supplement makers (HPC, SSF, faropenem API), copper-clad-laminate (CCL) and semiconductor-materials producers (NISSO-PB, 1,2-SBS, VP-POLYMER), thermal-paper manufacturers (color developers), battery-materials producers, industrial users of commodity chemicals, steelmakers (EAF dust treatment), and public/private construction clients (Engineering). End-markets: crop protection (fruit & vegetables first, expanding to grains), pharmaceuticals/nutraceuticals, semiconductors/electronics (AI servers, HBM, automotive chips), infrastructure, and environmental services. ### Independent characterization Nippon Soda is best understood as two engines and three stabilizers. The engines — Agri Business and specialty Chemical Materials — generated roughly 75% of FY3/26 segment operating profit (JPY 11.2 billion of JPY 14.97 billion before adjustments) on 60% of sales. Agri is cyclical and FX-sensitive (65.7% overseas sales ratio in FY3/26), while Chemical Materials has been structurally re-rated from a ~5–6% margin business to ~15–17% after exiting commodity lines (metallic sodium via Alkaline S.A.S., NISSO HI-CHLON, phenol-based color developers, sodium cyanide). The stabilizers (Trading & Logistics, Engineering, Eco Solutions) are low-growth and modest-margin but add scale and cash. A further, often-overlooked profit pillar is equity-method income (JPY 6.06 billion in FY3/26, chiefly Iharabras in Brazil), which made ordinary profit (JPY 22.99 billion) much larger than operating profit and is highly FX-sensitive (BRL/USD).
3 interactive charts drawn from the Methionine Hydroxy Analog Calcium Salt Market dataset — market size, regional splits and each segment breakdown. Open one to read its full data table and download it.
Global Methionine Hydroxy Analog Calcium Salt Market By Physical Form
Global Methionine Hydroxy Analog Calcium Salt Market By Livestock
Global Methionine Hydroxy Analog Calcium Salt Market By Region
Powering the world's best teams.
From next-gen startups to established enterprises.
Trusted by forward-thinking businesses
for data-driven intelligence
Co-Founder, Mojave Rail Fabrication Limited
This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job.
Manager, JavolVision
Thanks, I am so happy that we worked together. Maybe we still can work together in the future.
Sales Operations & Pricing Manager, Intel
Thanks. It's been a pleasure working with you, please use me as reference with any other Intel employees.
Sales Leader, Bamberg
We bought your "2025 report" in 2020. Everything is fine and very good.
Account and Business Manager, EFS-Holland BV
Thanks for sending the report it gives us a good global view of the Betaïne market.
Senior Retail Manager, LG Chem
We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.
Management Consultant, Level 21
I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.
Group Product Manager HVAC & Fire Protection GMA, Rockwool
I have been reading the first document or the study, the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!
R&D Director, Seojin
Thanks for your great support. Appreciate it. Well received report. It helps us to understand market well. We're planning other area of survey in the future, let's keep in touch.
Strategy & Business Development Director, Dogan Holding
We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.
Historical performance and forecast (2022–2032, USD Million)
Market Size (USD Million)
